Our findings underscore the importance of SMAD1 as a determinant of drug resistance in MM cells through across talk with NF-κB1, suggesting a SMAD1-based targeting strategy to overcome MM drug resistance. This evidence concerns the gene NFKB1 and Miyoshi myopathy.